已收盘 08-07 16:00:00 美东时间
+0.390
+0.52%
①周四,SpaceX首批股份解禁,当日股价小幅上涨,与市场预期并不一致;②摩根士丹利维持SpaceX增持评级,目标价300美元,预计其AI业务明年收入或达1000亿美元;③摩根大通、美银也看好SpaceX股价后续表现,但富国银行等因担忧AI支出过大下调目标价。
08-07 12:30
Kodiak Gas Services (KGS) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.39% Payable Aug. 27; for shareholders of record Aug. 17; ex-div Aug. 17. See KGS Dividend Scor...
08-06 11:01
华盛资讯8月6日讯,派杰投资公布2026财年Q2业绩,公司Q2营收4.96亿美元,同比增长24.9%,归母净利润0.68亿美元,同比增长60.8%。
08-06 02:32
Qualys' (QLYS) second quarter results demonstrated calculated current billings increasing by 16% year over year to $176.5M, which was its strongest growth in nearly three years, prompting positive fee...
08-05 21:15
Piper Sandler began coverage of neoclouds CoreWeave (CRWV) with an Overweight rating and $151 price target and Nebius (NBIS) with a Neutral rating and $224 price target. "We have a favorable view on t...
08-04 17:59
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in a tax-free all-stock transaction to form a diversified CNS biopharmaceutical company. The combined entity, named Supernus, Inc., will generate $2.2 billion in annual revenues and $125 million in cost synergies. Jack Khattar will serve as CEO, and the transaction is expected to close in Q4 2026. The merger combines complementary portfolios, enhances financial flexibility...
08-03 10:30
OceanFirst Financial (OCFC) declares $0.20/share quarterly dividend, in line with previous. Forward yield 4.07% Payable Aug. 21; for shareholders of record Aug. 10; ex-div Aug. 10. The Company’s Board...
07-31 21:05
GoDaddy (GDDY) shares tumbled 12% in premarket trading on Friday after the website development company reported quarterly results and guidance. Wall Street believes the pressure on the company is “acc...
07-31 19:29
Werewolf Therapeutics reported Q2 2026 results, including a $21M payment from asset transactions, enabling continued development of its INDUKINE and INDUCER platforms. Cash decreased to $22M, with collaboration revenue of $21M and net income of $3.7M. The company plans to update on strategic alternatives and clinical trials in H2 2026.
07-31 11:00